Tocilizumab and Rituximab in Systemic Sclerosis: A Real-Life Retrospective Observational Study Across Different Clinical Phenotypes.

J Pers Med · 2026 · PMC13117874 · PMID 42042553

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

borderline significancep = 0.056so close (0.05 < p ≤ 0.1)

In detail, TCZ-treated patients showed a significant decrease in FVC% both at T12 (β: −5.28, p = 0.019) and at T24 (β: −6.47, p = 0.04) with respect to T0, while, within RTX-treated patients, FVC% displayed a decrease in borderline significance at T12 compared to T0 (β: −5.22, p = 0.056).

also in 7,017 other papers

showed a trendno p-value reported

Although neither study met its primary endpoint of skin improvement, the TCZ group showed a trend toward mRSS reduction.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.